Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,506 GBX | -0.90% | -1.74% | -2.12% |
Apr. 02 | RBC Lifts Diploma PT, Maintains Sector Perform Rating | MT |
Apr. 02 | Bernstein starts AstraZeneca at 'outperform' | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 31.81 and 27.95 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.73 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.12% | 5.91B | C | ||
+4.34% | 38.65B | B | ||
+6.05% | 7.11B | C+ | ||
-8.95% | 5.15B | B | ||
+29.24% | 1.6B | C+ | ||
+3.26% | 1.52B | D+ | ||
-1.86% | 1.33B | C | ||
-2.94% | 1.02B | - | ||
+6.36% | 997M | B | ||
-9.61% | 972M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DPLM Stock
- Ratings Diploma PLC